Merck Submits Januvia/Metformin NDA Aiming To Launch First Fixed-Dose DPP-4 Inhibitor

Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet